^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADC2122

    i
    Other names: ADC2122, ZV0203, ADC-2122
    Company:
    Adcoris, Zhejiang Hisun, ZovaBio
    Drug class:
    HER2-targeted antibody-drug conjugate, Tubulin inhibitor
    Related drugs:
    over1year
    Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors (ESMO 2023)
    In preclinical studies, ZV0203 demonstrated superior antitumor activity compared to Kadcyla in multiple tumor cell line xenograft models with no noticeable toxicity. Conclusions ZV0203 has a manageable safety profile with preliminary antitumor activity in heavily pretreated pts with HER2+ cancer. Further evaluation at higher doses is underway.
    Clinical • P1 data • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • ADC2122
    over2years
    Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=36, Enrolling by invitation, Hangzhou Adcoris Biopharmacy Co., Ltd
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    ADC2122